Alkem Laboratories Ltd - 539523 - Board Meeting Intimation for Notice Of Meeting Of Board Of Directors Of The Company Scheduled To Be Held On 06Th August, 2021.
Alkem Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2021 ,inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2021. Kindly take note of the same. Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 and 47 read alongwith Schedule III of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulation"}, please find enclosed herewith a copy of advertisement published in today''s Newspapers viz. Business Standard (English) and Pratahkal (Marathi) informing about completion of dispatch of Notice of the 47th AGM alongwith Annual Report for the financial year 2020-21 through electronic mode and availability of e-voting facility available to the shareholders. The same is also available on the website of the Company at www.alkemlabs.com. Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Reg. 34 (1) Annual Report
Please find enclosed herewith the Notice of the 47th Annual General Meeting of the Company scheduled to be held on Friday, 27th August, 2021 at 11.00 a.m. through Video Conferencing (VC)/ Other Audio Visual Means (OAVM) alongwith the Annual Report for the financial year 2020-2021. The same is also available on the website of the Company at www.alkemlabs.com Kindly take the same on record. Alkem Laboratories Ltd - 539523 - Shareholding for the Period Ended June 30, 2021
Alkem Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here Alkem Laboratories Ltd - 539523 - Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aniruddha Singh Alkem Laboratories Ltd - 539523 - Disclosures under Reg. 10(7) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(7) in respect of acquisition under Regulation 10(1)(a)(i)of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dhananjay Kumar Singh Alkem Laboratories Ltd - 539523 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Mr Manish NarangDesignation :- Company Secretary and Compliance Officer Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 and 47 read along with Schedule III of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulation"), please find enclosed herewith a copy of advertisement published in today''s Newspapers viz. Business Standard (English) and Lakshadweep (Marathi) for information regarding 47th Annual General Meeting of the Company to be held through video conferencing (VC)/ other audio visual means (OAVM). The same is also available on the website of the Company at www.alkemlabs.com. Kindly take the same on record.
Alkem Laboratories hopes to fire up its US business to fuel future growth
Alkem Laboratories is currently the largest player in acute therapy and also owns Taxim, the first Rs 100 crore brand in the Indian pharma industry. Alkem Labs’ March 2021 quarter numbers were, however, below street expectations. Revenues grew in single digits and the 27% rise in net profit was mainly due to lower outgo during the quarter. The company’s stock price did not react negatively to the muted Q4FY21 results as Alkem Labs’ India business reported strong YoY recovery. (Alkem has in fact been flirting with its all time high this week. See stocks hitting all time highs today). Once the Covid-19 second wave recedes, investors are looking forward to Alkem Labs’ double-digit acute therapy growth coupled with US business being the next growth driver and its first biosimilar launched in March 2021 quarter. Quick Takes: Alkem Labs is the market leader in acute therapy with large mega brands such as Taxim, Ondem, Pan, Pan-D, A To Z, Clavam and Gemcal Operating margins might be impacted in the future due to rising prices of active pharmaceutical ingredients (API) and high packing material costs The management has guided for operating margins to be close to 20% in FY22 Alkem Labs’ new Indore manufacturing facility (SEZ) is awaiting pre-approval inspection by the US FDA Alkem Labs received form 483 with two observations after the USFDA conducted an inspection of its manufacturing facility at St. Louis in USA on June 14, 2021 India business recovery in Q4FY21 overshadowed by muted US market growth Alkem Labs reported 7% YoY growth in operating revenues at Rs 2,192 crore in the March 2021 quarter. While the India business recovered strongly in Q4FY21 with a rise of 17% YoY, US revenues fell 10% YoY. Other international market revenues increased 1.2% YoY. Operating margins fell 150 basis points (bps) YoY impacted by higher material costs (up 30% YoY), employee benefit expenses (up 24% YoY) and inventory provision of Rs 80 crore for one of the products in the US market. Operating margin came in at 13.28% in the March 2021 quarter. Net profit rose 27% YoY to Rs 240 crore mostly because of 80% YoY fall in tax expenses. Delta variant impact: Severity of Covid-19 second wave increases acute therapy demand Alkem Labs is India’s leading generic pharmaceutical company and the fifth largest in terms of sales. The business has roughly 4% market share in Indian pharma industry and is the market leader in acute therapy with major brands such as Taxim, Pan-D and Ondem. Acute therapy includes anti-infectives (primarily antibiotics, antifungal, antiviral), gastro-intestinal, pain management and vitamins/ minerals/ nutrients products. In the March 2021 quarter, more than 80% of Alkem Labs’ revenues came from acute therapies in the domestic market. The acute therapy sub-segment anti-infectives contributed nearly 40% of total segment revenues. Alkem Labs’ dominance in the anti-infective segment remains unchallenged for over a decade now. The company’s leading anti-infective product Taxim has 78% market share in anti-infective therapy. The acute therapy segment faced a severe downturn due to slowdown in new prescription generation, heightened focus on personal hygiene and sanitation, and lower mobility in H1FY21 due to the lockdown. Alkem Labs’ acute therapy segment growth declined 22% YoY in the June 2020 quarter and 12% YoY in the September 2020 quarter. Growth improved in the December 2020 quarter and by March 2021, momentum was back with double-digit growth in gastro intestinal (up 17% YoY), pain (up 10% YoY), vitamins (up 36% YoY), while anti-infectives reported flat growth. With the second wave of Covid-19 being deadlier than the first one and the presence of highly infectious Covid-19 variants, use of anti-infectives by doctors have increased. According to the management, higher cases of secondary infection of pneumonia, bacteria and fungus which were not present in the first Covid-19 wave are responsible for higher demand of anti-infectives. Yogesh Kaushal, President of Alkem Labs’ chronic division said there was strong traction in April and May 2021 in antibiotics which is expected to continue at least for 2-3 months. Thus, the June 2021 quarter is expected to be a strong one for acute therapy due to a lower base in the previous year’s corresponding June quarter, and doctors adopting aggressive regimens this time round to keep these secondary infections at bay. In addition to this, demand for multivitamins and nutrients are also not slowing down as fear of low immunity is now strongly embedded in the consumer psyche. Chronic business base to double in the next 3-4 years The chronic segment consists of neurology, dermatology, anti-diabetes and cardiology. Alkem Labs is an emerging player with its market share below 2% in the chronic segment. In the March 2021 quarter, the chronic product portfolio grew 18% YoY and 16% for FY21. Alkem Labs’ management is planning to launch new products that are going off patent in the next few years to drive growth in the chronic segment in the near future. The company is also open to acquisitions in the chronic segment but at reasonable valuations. Alkem Labs is mainly targeting growth in the cardiology and anti-diabetes segment as both these therapies constitute more than half of overall Indian pharma industry’s chronic revenues. Alkem Labs is in the process of building brands of Rs 50 -100 crore revenues in the next two years. Cardiac and diabetic therapies grew 13% and 27% YoY respectively in the March 2021 quarter. Both these therapies grew in double-digits in FY21 overall and are expected to maintain the same momentum as the management expects to double its chronic revenue base in the next 3-4 years. On an overall basis, domestic revenues (68% of total revenues) grew at a CAGR of 9% over the past five years. Domestic revenues stood at Rs 1,473 crore in Q4FY21. The management expects domestic revenues to grow in mid-teens in FY22. US business yet to reach its full potential, biosimilars in the offing A late entrant in the US market, Alkem Labs’ revenues grew at a CAGR of 20% over the past five years. The company entered the US market with the acquisition of Ascend Laboratories in 2010. The US pharmaceutical market is the second largest market for Alkem Labs, contributing 25% to its revenue base in Q4FY21. US revenues at Rs 544 crore fell 10% YoY in the March 2021 quarter. The fall in revenues was mainly due to decline in overall acute portfolio in the US market, fewer product launches during the quarter, loss of market share in one of its products and higher base of March 2020 quarter (driven by panic buying). The company launched 12 new products in FY21 and of the 19 product approvals received from the US FDA in FY21, less than 50% were launched. The remaining product approval basket will spill over into FY22, and along with new approvals, Alkem Labs is planning many product launches. According to the management, many of its products have peaked out and thus to augment revenue growth, market share and margins, new product launches are a prerequisite. The management guided for double-digit revenue growth of 15% for the US business in the near future. Speaking on the US market’s future growth trajectory, Alkem Labs’ Managing Director Sandeep Singh said the company has not yet reached its potential. He further added, “I think we are still less than half of what we can do in the US”. According to Alkem Labs’ management, the US will be the primary growth driver for the company in the next five years. Growth would be driven by the company’s strong product pipeline and biosimilars. Global biosimilar market is roughly $7 billion, and is expected to grow at a CAGR of 25-30% over the next five years. Even market leader Sun Pharma, after resisting for a number of years, is evaluating development of biosimilars and launching them by 2030. For Alkem Labs, India is the first market for the launch of its biosimilars. The company launched its first product in India in Q4FY21 through its subsidiary Enzene Bioscience. While the rest of its peer group is expanding into inhalers, dermatology, injectables, Alkem Labs largely depends on oral solids, and has chalked out its future plan of launching biosimilars in US and Europe in the next five years. And in the domestic market, the overall opportunity in the Enzene pipeline is close to Rs 2,000 crore. This will play out over the next 3-5 years. Investors would be keenly watching how the biosimilar opportunity converts into revenue growth. Alkem Laboratories Ltd - 539523 - Closure of Trading Window
This is to inform you that in terms of Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from 29th June, 2021 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter ended 30th June, 2021 are communicated to the Stock Exchanges.